Story perspectives

FDA Launches Pilot Program for Faster Health Reviews

10/23/2025

50 6

Summary

Story summary

The U.S. Food and Drug Administration (FDA) announced the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program on October 16, 2025.
The program aims to expedite regulatory reviews for health priorities, promising decisions within 1–2 months.
Among recipients is Follitropin Alfa + Lutropin Alfa (Pergoveris), to improve fertility care.
Tzield (teplizumab-mzwv) has been accepted for expedited review under the same program, signaling faster timelines for therapies.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) announced the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program on October 16, 2025.
The program aims to expedite regulatory reviews for health priorities, promising decisions within 1–2 months.
Among recipients is Follitropin Alfa + Lutropin Alfa (Pergoveris), to improve fertility care.
Tzield (teplizumab-mzwv) has been accepted for expedited review under the same program, signaling faster timelines for therapies.